---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-003779"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2024-05-22T23:59:59+00:00"
generated_at: "2026-06-01T09:43:53.919110+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences CEO Eisenberg and CSO Lockshin depart; CFO Parslow named interim CEO

## Summary
- Jeffrey F. Eisenberg stepped down as CEO and resigned as director effective May 16, 2024.
- Dr. Curtis Lockshin stepped down as Chief Scientific Officer, effective May 16, 2024.
- James F. Parslow, CFO since April 2017, appointed interim CEO; continues as principal financial officer.
- Parslow is a CPA with over 35 years experience; no related-party transactions or family relationships noted.
- Company advancing DNase oncology program toward Phase 1; preclinical data expected before year-end.

## SEC filing metadata
- accession: 0001683168-24-003779
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2024-05-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316824003779/0001683168-24-003779-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316824003779/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-003779
- JSON: https://secwatch.observer/filing/0001683168-24-003779.json
- Plain text: https://secwatch.observer/filing/0001683168-24-003779.txt

## Key facts
- Executive change
  Jeffrey F. Eisenberg resigned as Director at Xenetic Biosciences, Inc..
  - Action: resigned
  - Role: Director
  source text: and in connection therewith, Mr. Eisenberg resigned as a director of the Company and all of its subsidiaries, as applicable.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534525/000168316824003779/0001683168-24-003779-index.htm
- Executive change
  Dr. Curtis Lockshin departed as Chief Scientific Officer at Xenetic Biosciences, Inc..
  - Action: stepped down
  - Role: Chief Scientific Officer
  source text: In addition on May 16, 2024, the Company and Dr. Curtis Lockshin mutually agreed that Dr. Lockshin would step down as the Chief Scientific Officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534525/000168316824003779/0001683168-24-003779-index.htm
- Executive change
  Jeffrey F. Eisenberg departed as Chief Executive Officer at Xenetic Biosciences, Inc..
  - Action: stepped down
  - Role: Chief Executive Officer
  source text: On May 16, 2024, the Company and Jeffrey F. Eisenberg mutually agreed that Mr. Eisenberg would step down as the Chief Executive Officer of the Company, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534525/000168316824003779/0001683168-24-003779-index.htm
- Executive change
  James F. Parslow was appointed as Interim Chief Executive Officer at Xenetic Biosciences, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: On May 16, 2024, the Board of Directors (the “Board”) of Xenetic Biosciences, Inc. (the “Company”) appointed James F. Parslow, the Company’s Chief Financial Officer, to the position of Interim Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534525/000168316824003779/0001683168-24-003779-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.